...
机译:血液透析患者中白蛋白和轻链的中间截止值膜隙的试验评价:安全装置研究
Sunshine Coast Univ Hosp Dept Nephrol Birtinya Qld Australia;
Univ Queensland Ctr Kidney Dis Res Brisbane Qld Australia;
Univ Queensland Australasian Kidney Trials Network Brisbane Qld Australia;
Univ Queensland Australasian Kidney Trials Network Brisbane Qld Australia;
Univ Queensland Ctr Kidney Dis Res Brisbane Qld Australia;
UNSW George Inst Global Hlth Sydney NSW Australia;
Sydney Adventist Hosp San Renal Dialysis Unit Sydney NSW Australia;
Western Hlth Dept Nephrol Melbourne Vic Australia;
Concord Repatriat &
Gen Hosp Dept Nephrol Sydney NSW Australia;
Austin Hlth Dept Nephrol Melbourne Vic Australia;
Univ Queensland Ctr Kidney Dis Res Brisbane Qld Australia;
Univ Queensland Australasian Kidney Trials Network Brisbane Qld Australia;
Univ Queensland Australasian Kidney Trials Network Brisbane Qld Australia;
Royal Melbourne Hosp Dept Nephrol Parkville Vic Australia;
Univ Queensland Ctr Kidney Dis Res Brisbane Qld Australia;
Univ Queensland Australasian Kidney Trials Network Brisbane Qld Australia;
Albumin; Dialysis membrane; Dialyzer; Efficacy; Free light chains; Mid cut-off; Safety; Hemodialysis;
机译:血液透析患者中白蛋白和轻链的中间截止值膜隙的试验评价:安全装置研究
机译:MON-104 tRial评估血液透析患者白蛋白和轻链的中临界值膜清除率(REMOVAL-HD):单臂装置安全性研究
机译:去除高清研究的设计与方法:血液透析患者白蛋白和轻链的试验评价中截止值膜隙
机译:全身B2-微胶囊蛋白相关的氨基0SID0S1S在患者慢性肾功能衰竭,接受长期血液透析3年 - 光线和电子显微镜研究
机译:免疫调节药物来那度胺在淋巴瘤患者中的安全性和有效性:RU051417I-R-ICE(利妥昔单抗-异环磷酰胺-卡铂-依托泊苷)与来那度胺[R2-ICE]的I / II期开放标签研究的进展初次复发/原发性难治性弥漫性大B细胞淋巴瘤(DLBCL)。
机译:REMOVAL-HD研究的设计和方法:对血液透析患者中白蛋白和轻链的中临界值膜清除率的评估
机译:Mon-104试验评估血液透析患者中白蛋白和轻链的中间截止值膜清除(Removal-HD):单臂器件安全研究